Boron-based integrin-linked kinase (ILK) inhibitors for therapeutic and diagnostic uses
University of Kansas, KS, United States
Novel compounds and a method of treatment to reduce cyst growth in Polycystic Kidney Disease (PKD). The compounds target a key cellular pathway involved in aberrant proliferation in PKD, cancer, and neurological disorders. Compounds are synthesized using a unique approach to improve drug efficacy, specificity, solubility and cellular uptake.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Prototype
Technology Readiness Level: TRL 4
FIGURES OF MERIT
Value Proposition: Unique composition of matter patent application. Drug screenings showed the compounds inhibiting cell proliferation in nanomolar concentrations.
Organization Type: Academic/Gov Lab
Showcase Booth #: 13M
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date:
Primary Sources of Funding: University
Looking for: Both Funding and Development Partners